Stay updated on Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial
Sign up to get notified when there's something new on the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page.

Latest updates to the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page
- Check4 days agoChange DetectedThe record now includes published results for NCT02225587, citing a 2021 Hum Vaccin Immunother article and associated GMT data. This addition updates the study results section with analyzed outcomes.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check33 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference3%

- Check40 days agoChange DetectedRemoved multiple drug-safety topics and added a new version tag (v3.1.0), indicating a content cleanup and revision upgrade.SummaryDifference0.4%

- Check54 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and the Back to Top element was removed; no core content or critical data changed.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check69 days agoChange DetectedThe web page has undergone significant updates, including the addition of a new facility name and location, as well as new topics related to drug safety and vaccines, while removing previous location details and outdated drug information.SummaryDifference2%

Stay in the know with updates to Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page.